Season’s greetings from all of us at SenzaGen!

We wish you a truly happy holiday season, and we look forward to seeing you again in the new year.  

We wish you a truly happy holiday season, and we look forward to seeing you again in the new year.

 

Company presentation at Unicorn Summit in Stockholm

Our CEO presented at Vator Unicorn Summit in Stockholm last week and in the video below you can watch him explaining about SenzaGen’s change from a research organization to one with a strong focus on commercialization. Vator Unicorn Summit, November 27, 2019

Our CEO presented at Vator Unicorn Summit in Stockholm last week and in the video below you can watch him explaining about SenzaGen’s change from a research organization to one with a strong focus on commercialization.

Vator Unicorn Summit, November 27, 2019

Axel Sjöblad CEO of SenzaGen presenting at Biostock Live

In case you missed us at Biostock in Stockholm yesterday, CEO Axel Sjöblad explains SenzaGen’s commercialization and how the rights issue is part of the company’s growth strategy in these video clips. Presentation Biostock Live, Dec 3, 2019 Interview Biostock Live, Dec 3, 2019  

In case you missed us at Biostock in Stockholm yesterday, CEO Axel Sjöblad explains SenzaGen’s commercialization and how the rights issue is part of the company’s growth strategy in these video clips.

Presentation Biostock Live, Dec 3, 2019

Interview Biostock Live, Dec 3, 2019

 

VD Axel Sjöblads presentation på Småbolagsjakten

Lyssna på SenzaGens VD Axel Sjöblad via klippet nedan – om att ta bolaget från ett forskningsbolag till ett lönsamt kommersiellt bolag. SenzaGen på Småbolagsjakten i Stockholm den 27 november.

Lyssna på SenzaGens VD Axel Sjöblad via klippet nedan – om att ta bolaget från ett forskningsbolag till ett lönsamt kommersiellt bolag.

SenzaGen på Småbolagsjakten i Stockholm den 27 november.

SenzaGen på Stora Aktiedagen i Stockholm

Tack alla som kom och lyssnade på VD Axel Sjöblads presentation av SenzaGens skifte från forskningsbolag till kommersiellt bolag och den pågående företrädesemissionen på Stora Aktiedagen i Stockholm den 25 november 2019. Missade du presentationen så kan du se den här:

Tack alla som kom och lyssnade på VD Axel Sjöblads presentation av SenzaGens skifte från forskningsbolag till kommersiellt bolag och den pågående företrädesemissionen på Stora Aktiedagen i Stockholm den 25 november 2019.

Missade du presentationen så kan du se den här:

A new French distributor is joining us

We are proud to welcome PKDerm as GARD® distributor. Located in Grasse, France, PKDerm offers innovative in vitro solutions to pharmaceutical, dermo-cosmetic and chemical industries in order to evaluate the efficacy and safety of products likely to come into contact with the skin. “As a GARD distributor, we are excited to offer a solution to […]

We are proud to welcome PKDerm as GARD® distributor.

Located in Grasse, France, PKDerm offers innovative in vitro solutions to pharmaceutical, dermo-cosmetic and chemical industries in order to evaluate the efficacy and safety of products likely to come into contact with the skin.

“As a GARD distributor, we are excited to offer a solution to customers in various industries for their in vitro testing needs. GARD has shown impressive performance in skin sensitization, and its ability to evaluate a large variety of substances combined with potency measurement makes it truly unique. We expect the GARD assays to become an essential complement to our portfolio”, says Hanan Osman-Ponchet, PKDerm’s founder and CEO.

Hanan Osman-Ponchet, PKDerm’s founder and CEO.

Follow this link to contact PKDerm for your next or current testing project.

Welcome MB Research Labs to our partner network

We are excited to announce that another CRO has been fully trained on SenzaGen’s GARD technology platform and is offering GARDskin and GARDair services.   As a leading provider of in vitro toxicity testing to the US and worldwide, MB Research Labs is deeply committed to their customers and is dedicated to offering the latest […]

We are excited to announce that another CRO has been fully trained on SenzaGen’s GARD technology platform and is offering GARDskin and GARDair services.  

As a leading provider of in vitro toxicity testing to the US and worldwide, MB Research Labs is deeply committed to their customers and is dedicated to offering the latest predictive and innovative test methods.

We are delighted to have MB Research Laboratories in our partner network.

Dr. George DeGeorge and Dr. Michelle Cicchini of MB Research Laboratories performing the GARD assay.

MB Research Labs’ Website

Validation of the GARD™skin assay for assessment of chemical skin sensitizers – ring trial results of predictive performance and reproducibility

Toxicological Sciences, kfz108, https://doi.org/10.1093/toxsci/kfz108 Henrik Johansson, Robin Gradin, Angelica Johansson, Els Adriaens, Amber Edwards, Veronika Zuckerstätter, Anders Jerre, Florence Burleson, Helge Gehrke, Erwin Roggen Abstract Proactive identification of chemicals with skin sensitizing properties is a key toxicological endpoint within chemical safety assessment, as required by legislation for registration of chemicals. In order to meet demands of increased animal welfare and facilitate increased testing efficiency […]

Toxicological Sciences, kfz108, https://doi.org/10.1093/toxsci/kfz108

Henrik Johansson, Robin Gradin, Angelica Johansson, Els Adriaens, Amber Edwards, Veronika Zuckerstätter, Anders Jerre, Florence Burleson, Helge Gehrke, Erwin Roggen

Abstract
Proactive identification of chemicals with skin sensitizing properties is a key toxicological endpoint within chemical safety assessment, as required by legislation for registration of chemicals. In order to meet demands of increased animal welfare and facilitate increased testing efficiency also in non-regulatory settings, considerable efforts have been made to develop non-animal approaches to replace current animal testing.

Genomic Allergen Rapid Detection (GARD) is a state-of-the-art technology platform, the most advanced application of which is the assay for assessment of skin sensitizing chemicals, GARDskin. The methodology is based on a dendritic cell (DC)-like cell line, thus mimicking the mechanistic events leading to initiation and modulation of downstream immunological responses. Induced transcriptional changes are measured following exposure to test chemicals, providing a detailed evaluation of cell activation. These changes are associated with the immunological decision-making role of DCs in vivo and include among other phenotypic modifications, up-regulation of co-stimulatory molecules, induction of cellular and oxidative stress pathways and xenobiotic responses and provide a holistic readout of substance-induced DC activation.Here, results from an inter-laboratory ring trial of GARDskin, conducted in compliance with OECD guidance documents and comprising a blinded chemical test set of 28 chemicals, are summarized. The assay was found to be transferable to naïve laboratories, with an inter-laboratory reproducibility of 92.0%. The within-laboratory reproducibility ranged between 82.1-88.9%, while the cumulative predictive accuracy across the three laboratories was 93.8%.It was concluded that GARDskin is a robust and reliable method for the identification of skin sensitizing chemicals and suitable for stand-alone use or as a constituent of integrated testing. These data form the basis for the regulatory validation of GARDskin.Keywords
GARD™, GARD™skin, in vitro, sensitization, chemical sensitizers

Full article
Article on line ahead of print with open access 

Swedish influencer Margaux Dietz tests shampoo at SenzaGen

One of Sweden’s most famous influencers, Margaux Dietz, has visited SenzaGen in Lund. With support from the EU, SenzaGen has developed the world’s first animal-free test for respiratory allergies making our daily products safer. Margaux put a lab coat on and got to allergy test her own shampoo. Now, Margaux knows that the EU investments […]

One of Sweden’s most famous influencers, Margaux Dietz, has visited SenzaGen in Lund.

With support from the EU, SenzaGen has developed the world’s first animal-free test for respiratory allergies making our daily products safer. Margaux put a lab coat on and got to allergy test her own shampoo. Now, Margaux knows that the EU investments in innovations make a difference in everyday life.